Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-α/δ activation and increased mitochondrial fatty acid oxidation

Diabetes, Obesity and Metabolism

Volumn 11, Issue 4, 2009, Pages 304-314

  Løvås, Kristian ^a,b   Rost T H ^a,b   Skorve, J ^a   Ulvik, R J ^a,b   Gudbrandsen, O A ^a   Bohov, P ^a   Wensaas, A J ^c   Rustan, A C ^c   Berge, R K ^a,b   Husebye, E S ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Dyslipidaemia; PPAR agonist(s); TTA; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ATORVASTATIN; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SIMVASTATIN; TETRADECYLTHIOACETIC ACID; UNCLASSIFIED DRUG; 1-(CARBOXYMETHYLTHIO)TETRADECANE; ANTILIPEMIC AGENT; FATTY ACID; GLUCOSE BLOOD LEVEL; LIPID; LIPOPROTEIN; SULFIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CELL STRAIN HEPG2; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; MALE; MITOCHONDRION; MYOTUBE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; AGONISTS; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CELL CULTURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; SKELETAL MUSCLE; TUMOR CELL CULTURE;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; PPAR ALPHA; PPAR DELTA; SULFIDES; TUMOR CELLS, CULTURED;

EID: 61549119476     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00958.x     Document Type: Article

References (33)

1. Berge RK, Tronstad KJ, Berge K et al. The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie 2005; 87: 15-20.
2. Grav HJ, Tronstad KJ, Gudbrandsen OA et al. Changed energy state and increased mitochondrial beta-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression: Evidence for peroxisome proliferator-activated receptor-alpha independent induction of UCP-2 expression. J Biol Chem 2003; 278: 30525-30533.
3. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006; 116: 581-589.
4. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
5. Barish GD, Narkar VA, Evans RM. PPAR delta: A dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116: 590-597.
6. Tanaka T, Yamamoto J, Iwasaki S et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 2003; 100: 15924-15929.
7. Wang YX, Lee CH, Tiep S et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113: 159-170.
8. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 571-580.
9. Dyrøy E, Yndestad A, Ueland T et al. Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor alpha-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 2005; 25: 1364-1369.
10. Madsen L, Guerre-Millo M, Flindt EN et al. Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. J Lipid Res 2002; 43: 742-750.
11. Pettersen RJ, Salem M, Skorve J, Ulvik RJ, Berge RK, Nordrehaug JE. Pharmacology and safety of tetradecylthioacetic acid (TTA): Phase-1 study. J Cardiovasc Pharmacol 2008; 51: 410-417.
12. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
13. Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. J Lipid Res 1964; 5: 600-608.
14. Wergedahl H, Liaset B, Gudbrandsen OA et al. Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA: cholesterol acyltransferase activity in liver of Zucker rats. J Nutr 2004; 134: 1320-1327.
15. Vaagenes H, Muna ZA, Madsen L, Berge RK. Low doses of eicosapentaenoic acid, docosahexaenoic acid, and hypolipidemic eicosapentaenoic acid derivatives have no effect on lipid peroxidation in plasma. Lipids 1998; 33: 1131-1137.
16. Aas V, Kase ET, Solberg R, Jensen J, Rustan AC. Chronic hyperglycaemia promotes lipogenesis and triacylglycerol accumulation in human skeletal muscle cells. Diabetologia 2004; 47: 1452-1461.
17. Gaster M, Rustan AC, Aas V, Beck-Nielsen H. Reduced lipid oxidation in skeletal muscle from type 2 diabetic subjects may be of genetic origin: evidence from cultured myotubes. Diabetes 2004; 53: 542-548.
18. Wensaas AJ, Rustan AC, Løvstedt K et al. Cell-based multiwell assays for the detection of substrate accumulation and oxidation. J Lipid Res 2007; 48: 961-967.
19. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 2007; 56: 91-98.
20. Fredriksen J, Ueland T, Dyrøy E et al. Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy. Eur J Clin Invest 2004; 34: 709-715.
21. Lewis LA, Quaife ML, Page IH. Lipoproteins of serum, carriers of tocopherol. Am J Physiol 1954; 178: 221-222.
22. Horwitt MK, Harvey CC, Dahm CH Jr, Searcy MT. Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. Ann N Y Acad Sci 1972; 203: 223-236.
23. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006; 55 (Suppl. 2): S9-S15.
24. Madsen L, Frøyland L, Dyrøy E, Helland K, Berge RK. Docosahexaenoic and eicosapentaenoic acids are differently metabolized in rat liver during mitochondria and peroxisome proliferation. J Lipid Res 1998; 39: 583-593.
25. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91: 1770-1778.
26. Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim Biophys Acta 2003; 1633: 43-50.
27. Brady PS, Marine KA, Brady LJ, Ramsay RR. Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs. Biochem J 1989; 260: 93-100.
28. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 1998; 273: 16710-16714.
29. Riserus U, Sprecher D, Johnson T et al. Activation of PPAR delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress and increases fatty acid oxidation in moderately obese men. Diabetes 2008; 57: 382-339.
30. Berge K, Tronstad KJ, Flindt EN et al. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 2001; 22: 1747-1755.
31. Westergaard M, Henningsen J, Svendsen ML et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 2001; 116: 702-712.
32. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
33. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008; 28: 39-46.